Moongipa Capital Finance is a non-banking financial company that primarily trades in listed and unlisted securities and provides unsecured corporate and personal loans.
The company lacks a durable competitive advantage, as evidenced by an average net margin of -2.5% and a low ROCE of 5%. Its operations are largely dependent on volatile capital market trading and generic unsecured lending, which offer no pricing power or cost advantage.
Management has recently utilized a rights issue to expand into retail and electric vehicle financing, but historical returns on capital have been poor. The decision to withdraw a planned warrant issue due to market volatility suggests a lack of long-term strategic consistency.
The company's pivot into retail and electric vehicle financing, funded by a rights issue, failed to overcome its lack of scale and high cost of capital. As interest coverage plummeted from historical highs to near-breakeven levels, the negative cash conversion cycle drained liquidity, forcing the firm to take on expensive debt. The inherent volatility of its capital market trading operations eventually coincided with a credit downturn in the unsecured lending book, leading to a total erosion of the already thin 3.6% return on equity and a permanent impairment of shareholder capital.
RichFakir rates Moongipa Capital Finance Ltd's business quality as poor — 26/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Moongipa Capital Finance Ltd is trading about 19% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Moongipa Capital Finance Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Moongipa Capital Finance Ltd's fair value is about ₹15 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →